

IFW #



Docket No.: 066821-0233

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ruoslahti, Erkki I., et al.  
Appl. No. : 10/648,813  
Filed : August 25, 2003  
Title : COLLAGEN-BINDING MOLECULES THAT  
SELECTIVELY HOME TO TUMOR  
VASCULATURE AND METHODS OF  
USING SAME

Customer No.: 41552  
Confirmation No.: 5267

CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Dec 28, 2005.

*LaTangila Dennis*  
LaTangila Dennis

Grp./A.U. : 1642  
Examiner: : Yao, Lei

Mail Stop Amendment - IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

Also attached: 1 Information Disclosure Statement  
1 PTO Form 1449  
19 References

The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,


McDERMOTT WILL & EMERY LLP

*Deborah L. Cadena*

Deborah L. Cadena  
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122  
Phone: 858.535.9001 DLC:llf  
Facsimile: 858.597.1585  
Date: December 28, 2005

Please recognize our Customer No. 41552 as our  
correspondence address.



Docket No.: 066821-0233

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Ruoslahti, Erkki I., et al.  
Appl. No. : 10/648,813  
Filed : August 25, 2003  
Title : COLLAGEN-BINDING  
MOLECULES THAT SELECTIVELY  
HOME TO TUMOR  
VASCULATURE AND METHODS  
OF USING SAME

Customer No.: 41552  
Confirmation No.: 5267

**CERTIFICATE OF MAILING (37 CFR. § 1.8(a))**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Dec 28, 2005.

*LaTangila Dennis*  
LaTangila Dennis

Grp./A.U. : 1642  
Examiner: : Yao, Lei

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment - IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

01/05/2006 RMEBRAHT 00000041 502624 10648813

01 FC:1806 180.00 DA

10/648,813

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 502624.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP




Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122  
Phone: 858.535.9001 DLC:HGF:llf  
Facsimile: 858.597.1585  
**Date: December 28, 2005**

**Please recognize our Customer No. 41552  
as our correspondence address.**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	ATTY. DOCKET NO. <b>066821-233</b>	SERIAL NO. <b>10/648,813</b>
	APPLICANT <b>Ruoslahti, et al.</b>	
	FILING DATE <b>August 25, 2003</b>	GROUP <b>1642</b>

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5,320,970	06-14-1994	Eyre et al.	
	2.	US 5,541,295	07-30-1996	Barrach et al.	
	3.	US 5,763,272	06-09-1998	Naser et al.	
	4.	US 6,030,792	02-29-2000	Otterness et al.	
	5.	US 6,132,976	10-17-2000	Poole et al.	
	6.	US 2003/0113331 A1	06-19-2003	Brooks et al.	
	7.	US 2004/0091482 A9	05-13-2004	Watkins et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number 4 - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
	8.	EP 0 510 949 A2	10-28-1992	Pouletty, P.		
	9.	EP 0 921 395 A2	12-11-1998	Downs et al.		
	10.	WO 94/14070 A1	06-23-1994	Poole et al.		
	11.	WO 95/04282 A1	02-09-1995	Naser et al.		
	12.	WO 97/44059 A2	11-27-1997	Poole et al.		
	13.	WO 98/35235 A1	08-13-1998	Hollander et al.		
	14.	WO 99/06840 A1	02-11-1999	Krane et al.		
	15.	WO 00/40597	07-13-2000	Brooks et al.		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
---------------------	----------	---

	16.	Bellon, "Quantification and specific detection of collagenous proteins using an enzyme-linked immunosorbent assay and an immunoblotting for cyanogen bromide peptides," <u>Analytical Biochemistry</u> 150, 188-202 (1985).	
	17.	Borza et al., "The Goodpasture Autoantigen," <u>J. Biol. Chem.</u> 275(8):6030-6037 (2000).	
	18.	David et al., "Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen," <u>J. Biol. Chem.</u> 276(9):6370-6377 (2001).	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached

INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	066821-233	10/648,813
	APPLICANT	
	Ruoslahti, et al.	
	FILING DATE	GROUP
	August 25, 2003	1642

	19.	Kalluri et al., "Specificity of circulating and tissue-bound autoantibodies in Goodpasture Syndrome," <u>Pro. Assoc. Am. Physicians</u> 108(2):134-139 (1996).	
	20.	Nakanishi et al., "Immunohistochemical study of $\alpha$ 1-5 chains of type IV collagen in hereditary nephritis," <u>Kid. Inter.</u> 46:1413-1421 (1994).	
	21.	Timpl, "Antibodies to collagens and procollagens," <u>Methods in Enzymology</u> 82:472-498 (1982).	
	22.	Wheatcroft et al., "Evidence of in situ stability of the type IV collagen triple helix in human inflammatory bowel disease using a denaturation of specific epitope antibody," <u>Matrix Biology</u> 18:361-372 (1999).	
	23.	Wick et al., "Characterization of antibodies to basement membrane (type iv) collagen in immunohistological studies," <u>Immunobiol.</u> 156:372-381 (1979).	
	24.	Xu et al., "Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization," <u>Hybridoma</u> , 19(5): 375-385 (2000).	
	25.	Xu et al., "Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo," <u>J. Cell Biol.</u> , 154(5):1069-1079 (2001).	
	26.	Yoshioka et al., "Type IV collagen $\alpha$ 5 chain," <u>Am. J. Path.</u> 144(5):986-996 (1994).	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached